Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Licensing agreement uncertainty

<< Previous

Bullboard Posts

Next >>

Comment by MirrorWorldManon Oct 06, 2022 10:56pm

166 Views

Post# 35011385

RE:RE:Licensing agreement uncertainty

Thats not good enough of a response. How much is the penalty? What is the permitted maximum time frame for launch? What are the milestone markers, the royalty percentage. What is it with this company and presenting real dates and numbers? Again, Howie wants investors to give real dollars to Sirona but will not give any real numbers on in return. Words and hype, stupid smiles and pictures of people in a meeting never did matter

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments